Mr. Foote has worked on Africa-related issues for over 40 years in a bipartisan manner – successfully collaborating with both Republican and Democratic administrations. Mr. Foote has advised U.S. administrations on key Africa Policy initiatives and participated in numerous senior-level sessions with Administration officials and Members of Congress. Over the years, Mr. Foote has developed one of the broadest and most influential networks of senior policy-makers and decision-makers in the U.S., Africa, and throughout the African Diaspora.
Mr. Foote will continue to lend his considerable experience and expertise to CBIS’ International Government Affairs Advisory Board. In this capacity, Mr. Foote will advise the Company on its research and drug-development initiatives in Africa and help CBIS forge new partnerships and collaborations with stakeholders worldwide.
In 2016, a CBIS delegation, led by Mr. Dabney including Mr. Foote, visited South Africa and Namibia. The CBIS delegation held high-level meetings with representatives from government, private sector, academia, civil society, and media. This visit established the foundation for the Company’s current activities in Africa.
Not long after this initial Africa trip, the Company developed a research collaboration with Stellenbosch University, one of the oldest Universities in South Africa, to investigate the use of cannabinoids to treat chronic pain and other indications. CBIS and Stellenbosch University have begun clinical studies targeting Chronic Pelvic Pain Management, and plan to investigate additional indications, include various Cancers, HIV/AIDS, and PTSD. These initial studies are being conducted in South Africa, and a second study has been initiated in Nigeria under Stellenbosch’s direction.
Mr. Foote has been instrumental in assisting CBIS in expanding its global research collaborations and expanding the Company’s Global Research Consortium. Through CFA’s annual Ronald H. Brown African Affairs Series platform, Mr. Foote initiated the Company’s relationship with the Dana-Farber Cancer Institute at Harvard Medical School. CBIS’ collaboration with Dana-Farber has grown into a 5-year, $1.8 million research agreement. Activities included in the Company’s collaboration with the Dana-Farber Cancer Institute include the investigation of cannabinoids to treat various forms of cancer, and potentially other indications.
To date, Dana-Farber and CBIS have jointly published two peer-reviewed articles in the journalFrontiers in Oncology. Additionally, CBIS has participated in the Global Health Catalyst (GHC) Summit at Harvard Medical School the last two years.
CBIS’ CEO, Mr. Dabney, has lectured at Harvard Medical Schoola number of times, includingpresenting the Company’s initiatives at the Harvard Medical School GHC Summit, and was honored with theesteemedGHC Harvard Medical School Industry Leadership Award at the 2018 Summit.